# Aprepitant

## EMEND 125mg

##### 

| TAH Drug Code      | OEM125                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy.                                                                                                          |
| Dosing             | Given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hour prior to chemotherapy (day 1) and 80 mg once daily in the morning on day 2 and day 3.                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                            |
| Contraindications  | Concurrent administration with pimozide, terfenadine, astemizole, or cisapride.                                                                                                                                                                          |
| Adverse Effects    | Hiccups, asthenia/fatigue, ALT increased, constipation, headache, anorexia. Central nervous system: Fatigue (?18%) Gastrointestinal: Nausea (6% to 13%), constipation (9% to 10%) Neuromuscular & skeletal: Weakness (?18%) Miscellaneous: Hiccups (11%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                             |

